Dimensional Fund Advisors LP lifted its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 24.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 863,760 shares of the biopharmaceutical company's stock after acquiring an additional 170,968 shares during the quarter. Dimensional Fund Advisors LP owned 1.76% of Puma Biotechnology worth $2,635,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the stock. Marshall Wace LLP acquired a new position in shares of Puma Biotechnology in the 4th quarter worth approximately $261,000. Walleye Capital LLC acquired a new stake in Puma Biotechnology during the 4th quarter worth approximately $118,000. XTX Topco Ltd lifted its holdings in Puma Biotechnology by 126.2% during the 4th quarter. XTX Topco Ltd now owns 59,674 shares of the biopharmaceutical company's stock worth $182,000 after buying an additional 33,290 shares in the last quarter. Barclays PLC lifted its holdings in Puma Biotechnology by 13.3% during the 4th quarter. Barclays PLC now owns 88,407 shares of the biopharmaceutical company's stock worth $270,000 after buying an additional 10,386 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its holdings in Puma Biotechnology by 36.5% during the 4th quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company's stock worth $2,469,000 after buying an additional 216,329 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.
Puma Biotechnology Stock Performance
NASDAQ:PBYI traded up $0.04 during trading hours on Tuesday, reaching $3.62. 17,158 shares of the company's stock were exchanged, compared to its average volume of 440,260. The firm has a market capitalization of $179.42 million, a price-to-earnings ratio of 7.53 and a beta of 1.29. The company has a 50-day moving average of $3.07 and a 200 day moving average of $3.06. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 1-year low of $2.23 and a 1-year high of $4.83.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The firm had revenue of $59.10 million during the quarter, compared to analysts' expectations of $52.50 million. Research analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th. StockNews.com raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 11th.
Read Our Latest Analysis on Puma Biotechnology
About Puma Biotechnology
(
Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Read More
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
